PMID- 35379069
OWN - NLM
STAT- MEDLINE
DCOM- 20220523
LR  - 20220523
IS  - 1744-7666 (Electronic)
IS  - 1465-6566 (Linking)
VI  - 23
IP  - 7
DP  - 2022 May
TI  - Drug treatment strategies for eosinophilic esophagitis in adults.
PG  - 827-840
LID - 10.1080/14656566.2022.2060077 [doi]
AB  - INTRODUCTION: Eosinophilic esophagitis (EoE) is a clinical and pathological 
      disorder, characterized by symptoms of esophageal dysfunction, and 
      eosinophil-predominant inflammation restricted to the esophagus. Treatment 
      outcomes include symptomatic remission, histological and endoscopic normalization 
      and improving quality of life. Besides dietary modifications and endoscopic 
      dilation, drugs available are swallowed topical corticosteroids (STCs) with 
      reduced bioavailability and proton pump inhibitors (PPI). AREAS COVERED: Herein, 
      the authors review the current treatment strategies for EoE in adults, providing 
      the reader with their expert perspectives. The authors give discussion to the 
      value of PPIs as a first-line therapy for EoE, in addition to the use of STCs. 
      The current development of new formulations of STCs targeting the esophagus and 
      novel therapies aimed at blocking molecular pathways are also discussed. Finally, 
      the authors briefly look at the value of monoclonal antibodies targeting IL-5RA, 
      IL-13, IL-4 or Siglec8, and oral S1PR agonists to the treatment of EoE. EXPERT 
      OPINION: Viscose formulations of STC designed to coat the esophagus and new 
      effervescent orodispersible tablets provide increased effectiveness at low doses. 
      Investigational therapies that target several Th2-associated diseases seem useful 
      in EoE. Comparative effectiveness and cost-utility analyses will help to position 
      them in a complex therapeutic scenario.
FAU - Lucendo, Alfredo J
AU  - Lucendo AJ
AUID- ORCID: 0000-0003-1183-1072
AD  - Department of Gastroenterology. Hospital General de Tomelloso, Tomelloso, Spain.
AD  - Instituto de Investigacion Sanitaria La Princesa, Spain.
AD  - Instituto de Investigacion Sanitaria de Castilla-La Mancha (IDISCAM).
AD  - Centro de Investigacion Biomedica en Red Enfermedades Hepaticas y Digestivas 
      (CIBERehd), Spain.
LA  - eng
PT  - Journal Article
DEP - 20220404
PL  - England
TA  - Expert Opin Pharmacother
JT  - Expert opinion on pharmacotherapy
JID - 100897346
RN  - 0 (Glucocorticoids)
RN  - 0 (Proton Pump Inhibitors)
SB  - IM
MH  - Adult
MH  - *Eosinophilic Esophagitis/diagnosis/drug therapy/pathology
MH  - Glucocorticoids/therapeutic use
MH  - Humans
MH  - Proton Pump Inhibitors/therapeutic use
MH  - Quality of Life
OTO - NOTNLM
OT  - Biological therapy
OT  - benralizumab
OT  - budesonide
OT  - cendakimab
OT  - dupilumab
OT  - eosinophilic esophagitis
OT  - etrasimod
OT  - fluticasone
OT  - food-elimination diet
OT  - mepolizumab
OT  - proton pump inhibitor
OT  - reslizumab
OT  - swallowed topical corticosteroids
EDAT- 2022/04/06 06:00
MHDA- 2022/05/24 06:00
CRDT- 2022/04/05 05:26
PHST- 2022/04/06 06:00 [pubmed]
PHST- 2022/05/24 06:00 [medline]
PHST- 2022/04/05 05:26 [entrez]
AID - 10.1080/14656566.2022.2060077 [doi]
PST - ppublish
SO  - Expert Opin Pharmacother. 2022 May;23(7):827-840. doi: 
      10.1080/14656566.2022.2060077. Epub 2022 Apr 4.